126 related articles for article (PubMed ID: 22672805)
1. Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas.
Quinones W; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Feb; 17(1):41-4. PubMed ID: 22672805
[TBL] [Abstract][Full Text] [Related]
2. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
3. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
4. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic adenoma: an immunohistochemical analysis using biotin-free methods.
Ortiz-Rey JA; Antón-Badiola I; Pérez-Pedrosa A; Peteiro-Cancelo Á; González-Carreró J
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):386-91. PubMed ID: 22495376
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
7. [Pathological and immunohistochemical analyses of 32 cases of nephrogenic adenoma].
Shen Q; Sun LH; Wang JH; Liu LB; He Q; Jin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 45(4):522-6. PubMed ID: 23939154
[TBL] [Abstract][Full Text] [Related]
8. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
[TBL] [Abstract][Full Text] [Related]
9. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison.
Gilcrease MZ; Delgado R; Vuitch F; Albores-Saavedra J
Hum Pathol; 1998 Dec; 29(12):1451-6. PubMed ID: 9865832
[TBL] [Abstract][Full Text] [Related]
10. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
11. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Skinnider BF; Oliva E; Young RH; Amin MB
Am J Surg Pathol; 2004 Jun; 28(6):701-5. PubMed ID: 15166661
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
13. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
Cossu-Rocca P; Contini M; Brunelli M; Festa A; Pili F; Gobbo S; Eccher A; Mura A; Massarelli G; Martignoni G
Am J Surg Pathol; 2009 Jul; 33(7):1031-6. PubMed ID: 19384190
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic adenoma of the urinary tract: a review.
Alexiev BA; LeVea CM
Int J Surg Pathol; 2012 Apr; 20(2):123-31. PubMed ID: 22415059
[TBL] [Abstract][Full Text] [Related]
15. Can We Identify Nephrogenic Adenoma in Urine Cytology Specimens? A Study Evaluating Previously Described Cytomorphologic Features in Correlation With PAX8 Immunohistochemical Staining Results.
McCroskey Z; Pambuccian SE; Wojcik EM; Barkan GA
Am J Clin Pathol; 2016 Mar; 145(3):373-8. PubMed ID: 27124920
[TBL] [Abstract][Full Text] [Related]
16. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
18. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Xiao GQ; Burstein DE; Miller LK; Unger PD
Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]